Folgen
Marcel Philipp Trefny
Marcel Philipp Trefny
Universitätsspital Basel
Bestätigte E-Mail-Adresse bei med.uni-muenchen.de
Titel
Zitiert von
Zitiert von
Jahr
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ...
Nature medicine 24 (7), 994-1004, 2018
8762018
Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12
CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, ...
Immunity 49 (6), 1148-1161. e7, 2018
7622018
CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
H Wang, F Franco, YC Tsui, X Xie, MP Trefny, R Zappasodi, SR Mohmood, ...
Nature immunology 21 (3), 298-308, 2020
3882020
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
MA Stanczak, SS Siddiqui, MP Trefny, DS Thommen, KF Boligan, ...
The Journal of clinical investigation 128 (11), 4912-4923, 2018
2292018
Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
AL Correia, JC Guimaraes, P Auf der Maur, D De Silva, MP Trefny, ...
Nature 594 (7864), 566-571, 2021
1712021
Magnesium sensing via LFA-1 regulates CD8+ T cell effector function
J Lötscher, AAM i Líndez, N Kirchhammer, E Cribioli, G Giordano, ...
Cell, 2022
942022
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
MP Trefny, M Kaiser, MA Stanczak, P Herzig, S Savic, M Wiese, ...
Cancer Immunology, Immunotherapy 69 (8), 1505-1517, 2020
692020
Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade
MA Stanczak, NR Mantuano, N Kirchhammer, DE Sanin, J Wang, ...
BioRxiv, 2021
642021
GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses
AS Kashyap, L Fernandez-Rodriguez, Y Zhao, G Monaco, MP Trefny, ...
Cell reports 28 (13), 3367-3380. e8, 2019
442019
A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer
MP Trefny, SI Rothschild, F Uhlenbrock, D Rieder, B Kasenda, ...
Clinical Cancer Research 25 (10), 3026-3034, 2019
352019
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity
N Kirchhammer, MP Trefny, M Natoli, D Brücher, SN Smith, F Werner, ...
Science Translational Medicine 14 (653), eabm9043, 2022
342022
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy
MP Trefny, N Kirchhammer, P Auf der Maur, M Natoli, D Schmid, ...
Nature Communications 14 (1), 86, 2023
202023
Biochemical re-programming of human dermal stem cells to neurons by increasing mitochondrial membrane potential
H Liu, Z He, SL April, MP Trefny, JS Rougier, S Salemi, R Olariu, ...
Cell Death & Differentiation 26 (6), 1048-1061, 2019
112019
N-acetylcysteine overcomes NF1 loss-driven resistance to PI3Kα inhibition in breast cancer
PA der Maur, MP Trefny, Z Baumann, M Vulin, AL Correia, M Diepenbruck, ...
Cell Reports Medicine, 2023
42023
Successful IL-12 cancer immunotherapy requires NK cell-derived CCL5 for anti-tumor DC-T cell crosstalk
N Kirchhammer, MP Trefny, M Natoli, D Brücher, SN Smith, F Werner, ...
bioRxiv, 2021
22021
Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity
L Fernandez-Rodriguez, C Cianciaruso, R Bill, MP Trefny, R Klar, ...
Journal for Immunotherapy of Cancer 11 (5), 2023
12023
Unraveling T-cell Exhaustion: Genetic Screening Meets In Vitro Modeling
D Schmid, P Auf der Maur, MP Trefny, A Zippelius
Cancer Research 83 (23), 3830-3832, 2023
2023
Multimodal single-cell profiling of T cell specificity and reactivity in lung cancer
F Bieberich, R Vazquez-Lombardi, H Jin, KL Hong, P Herzig, M Trefny, ...
bioRxiv, 2023.10. 04.560863, 2023
2023
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–18